FDA Approves Improved Performance Of OnGuard Chest X-ray Computer-Aided Detection Technology of Riverain Medical
Riverain Medical® has announced that the U.S. Food and Drug Administration (FDA) has granted approval for the newest version of the OnGuard™ Chest X-ray Computer-Aided Detection (CAD) technology. OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest X-ray. This improved performance demonstrates a 73% reduction in false positive marks and 50% higher relative sensitivity compared to the original product.
Read the full story here
-
Ranplex CRC advances bowel cancer detection technology
Breath test for early detection of lung cancer
FDA Approves Cysview Technique
Transgenomic Expands Distribution Of SURVEYOR(R) Scan K-RAS Mutation Detection Kit With CE IVD Mark
Siemens Launches Advia Centaur Tests In Europe
